Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 345
Filtrer
1.
Microbiol Spectr ; 12(6): e0410523, 2024 Jun 04.
Article de Anglais | MEDLINE | ID: mdl-38700337

RÉSUMÉ

Resistance to ceftazidime-avibactam (CZA) due to Klebsiella pneumoniae carbapenemase (KPC) variants is increasing worldwide. We characterized two CZA-resistant clinical Klebsiella pneumoniae strains by antimicrobial susceptibility test, conjugation assays, and WGS. Isolates belonged to ST258 and ST45, and produced a KPC-31 and a novel variant KPC-197, respectively. The novel KPC variant presents a deletion of two amino acids on the Ω-loop (del_168-169_EL) and an insertion of two amino acids in position 274 (Ins_274_DS). Continued surveillance of KPC variants conferring CZA resistance in Colombia is warranted. IMPORTANCE: Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of Klebsiella pneumoniae carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.


Sujet(s)
Antibactériens , Composés azabicycliques , Protéines bactériennes , Ceftazidime , Association médicamenteuse , Multirésistance bactérienne aux médicaments , Infections à Klebsiella , Klebsiella pneumoniae , Tests de sensibilité microbienne , bêta-Lactamases , Composés azabicycliques/pharmacologie , Ceftazidime/pharmacologie , Klebsiella pneumoniae/génétique , Klebsiella pneumoniae/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/enzymologie , Colombie , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Humains , Antibactériens/pharmacologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Multirésistance bactérienne aux médicaments/génétique , Infections à Klebsiella/microbiologie , Infections à Klebsiella/traitement médicamenteux
2.
Rev. chil. infectol ; 41(1): 36-49, feb. 2024. tab
Article de Espagnol | LILACS | ID: biblio-1559664

RÉSUMÉ

La resistencia antimicrobiana es una amenaza para los logros de la medicina moderna y una de las medidas más efectivas para contrarrestarla son los programas de optimización del uso de antimicrobianos (PROA), en el cual el laboratorio de microbiología es uno de los principales componentes. La aplicación efectiva de tecnología de la información en los procesos es fundamental, pero existe poca información en Latinoamérica sobre el desarrollo y la articulación de las herramientas tecnológicas para apoyar los PROA. Este consenso hace recomendaciones sobre la gestión de los datos microbiológicos para la toma de decisiones. En la Parte I, se presentan las recomendaciones en cuanto al uso de un sistema informatizado de gestión de datos microbiológicos en la práctica clínica, los requerimientos de datos y de reporte en el laboratorio de microbiología, y los contenidos del sistema de gestión de calidad avanzado en el laboratorio. En la Parte II, se discuten los requerimientos de información para la gestión de PROA en estadios intermedios, iniciales y avanzados por el laboratorio y la farmacia; así como la integración del equipo de PROA con el Comité de Prevención y Control de Infecciones y la información para la gestión de PROA a nivel gerencial.


Antimicrobial resistance is a threat to the achievements of modern medicine and one of the most effective measures to counteract it is antimicrobial use optimization programs (AMS), in which the microbiology laboratory is one of the main components. The effective application of information technology in the processes is fundamental, but there is little information in Latin America on the development and articulation of technological tools to support AMSs. This consensus makes recommendations on the management of microbiological data for decision making. In Part I, recommendations on the use of a computerized microbiological data management system in clinical practice, data and reporting requirements in the microbiology laboratory, as well as the contents of the advanced quality management system in the laboratory are presented. In Part II, the information requirements for AMS management in intermediate, initial, and advanced stages by the laboratory and pharmacy are discussed; as well as the integration of the AMS team with the Infection Prevention and Control Committee and the information for AMS management at the management level.


Sujet(s)
Humains , Consensus , Gestion responsable des antimicrobiens , Informatique médicale , Tests de sensibilité microbienne , Techniques microbiologiques , Systèmes d'information de laboratoire d'analyses médicales , Gestion des données , Amérique latine
3.
Lancet Infect Dis ; 24(4): 395-403, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38218194

RÉSUMÉ

BACKGROUND: More than six million people worldwide, particularly in vulnerable communities in Latin America, are infected with Trypanosoma cruzi, the causative agent of Chagas disease. Only a small portion have access to diagnosis and treatment. Both drugs used to treat this chronic, neglected infection, benznidazole and nifurtimox, were developed more than 50 years ago, and adverse drug reactions during treatment pose a major barrier, causing 20% of patients to discontinue therapy. Fexinidazole proved efficacious in an earlier, interrupted clinical trial, but the doses evaluated were not well tolerated. The present study evaluated fexinidazole at lower doses and for shorter treatment durations. METHODS: In this randomised, double-blind, phase 2 trial, we included adult patients (18-60 years old) with confirmed T cruzi infection by serology and PCR and without signs of organ involvement. We evaluated three regimens of fexinidazole-600 mg once daily for 10 days (6·0 g total dose), 1200 mg daily for 3 days (3·6 g), and 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6·6 g)-and compared them with a historical placebo control group (n=47). The primary endpoint was sustained negative results by PCR at end of treatment and on each visit up to four months of follow-up. This study is registered with ClinicalTrials.gov, NCT03587766, and EudraCT, 2016-004905-15. FINDINGS: Between Oct 16, 2017, and Aug 7, 2018, we enrolled 45 patients (n=15 for each group), of whom 43 completed the study. Eight (19%) of 43 fexinidazole-treated patients reached the primary endpoint, compared with six (13%) of 46 in the historical control group. Mean parasite load decreased sharply following treatment but rebounded beginning 10 weeks after treatment. Five participants had seven grade 3 adverse events: carpal tunnel, sciatica, device infection, pneumonia, staphylococcal infection, and joint and device dislocation. Two participants discontinued treatment due to adverse events unrelated to fexinidazole. INTERPRETATION: The fexinidazole regimens in this study had an acceptable safety profile but did not prove effective against T cruzi infection. Development of fexinidazole monotherapy for treating T cruzi infection has been stopped. FUNDING: The Drugs for Neglected Diseases initiative.


Sujet(s)
Maladie de Chagas , Nitroimidazoles , Trypanosoma cruzi , Adulte , Humains , Adolescent , Jeune adulte , Adulte d'âge moyen , Résultat thérapeutique , Maladie de Chagas/traitement médicamenteux , Nifurtimox/effets indésirables , Méthode en double aveugle
4.
Microbiol Spectr ; 12(1): e0262323, 2024 Jan 11.
Article de Anglais | MEDLINE | ID: mdl-38084974

RÉSUMÉ

IMPORTANCE: The antimicrobial resistance of Helicobacter pylori (Hp) currently poses a threat to available treatment regimens. Developing antimicrobial drugs targeting new bacterial targets is crucial, and one such class of drugs includes Hp-flavodoxin (Hp-fld) inhibitors that target an essential metabolic pathway in Hp. Our study demonstrated that combining these new drugs with conventional antibiotics used for Hp infection treatment prevented the regrowth observed with drugs used alone. Hp-fld inhibitors show promise as new drugs to be incorporated into the treatment of Hp infection, potentially reducing the development of resistance and shortening the treatment duration.


Sujet(s)
Anti-infectieux , Infections à Helicobacter , Helicobacter pylori , Humains , Flavodoxine/métabolisme , Helicobacter pylori/métabolisme , Anti-infectieux/pharmacologie , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Infections à Helicobacter/traitement médicamenteux , Infections à Helicobacter/microbiologie
6.
Biomedica ; 43(4): 457-473, 2023 12 01.
Article de Espagnol | MEDLINE | ID: mdl-38109138

RÉSUMÉ

Introduction: Antimicrobial resistance surveillance is a fundamental tool for the development, improvement, and adjustment of antimicrobial stewardship programs, therapeutic guidelines, and universal precautions to limit the cross-transmission of resistant bacteria between patients. Since the beginning of 2020, the SARS-CoV-2 pandemic profoundly challenged the health system and, according to some reports, increased the rates of antimicrobial resistance. Objective: To describe the behavior of antimicrobial resistance of the most frequent bacterial pathogens in twenty Colombian hospitals from January 2018 to December 2021. Materials and methods: We conducted a descriptive study based on the microbiological information recorded from January 2018 to December 2021 in twenty levels III and IV health institutions in twelve Colombian cities. We identified the species of the ten most frequent bacteria along with their resistance profile to the antibiotic markers after analyzing the data through WHONET. Results: We found no statistically significant changes in most pathogens' resistance profiles from January 2018 to December 2021. Only Pseudomonas aeruginosa had a statistically significant increase in its resistance profile, particularly to piperacillin/tazobactam and carbapenems. Conclusions: The changes in antimicrobial resistance in these four years were not statistically significant except for P. aeruginosa to piperacillin/tazobactam and carbapenems.


Introducción: El comportamiento de la resistencia antimicrobiana es fundamental en el mejoramiento y ajuste de los programas de optimización de uso de antimicrobianos, la implementación de las guías terapéuticas y las precauciones que limitan la transmisión cruzada de bacterias resistentes entre pacientes. Desde el inicio del 2020, la pandemia del SARS-CoV-2 desafió profundamente al sistema de salud y, según algunos reportes, aumentó las tasas de resistencia antimicrobiana. OBJETIVO: Describir el comportamiento de la resistencia antimicrobiana en los microrganismos más frecuentes en veinte hospitales colombianos durante el periodo 2018-2021. Materiales y métodos: Se trata de un estudio descriptivo basado en la información microbiológica reportada por veinte instituciones de salud de nivel III y IV, entre enero de 2018 y diciembre de 2021, en doce ciudades de Colombia, las cuales hacen parte del "Grupo para el estudio de la resistencia nosocomial en Colombia", liderado por la Universidad El Bosque. La identificación de género y especie de los microorganismos más frecuentes, junto con su perfil de resistencia frente a antibióticos marcadores, se determinaron mediante el análisis de los datos vía WHONET. RESULTADOS: En general, los 10 microorganismos más frecuentes analizados a lo largo de los 4 años no presentaron cambios estadísticamente significativos en sus perfiles de resistencia durante los cuatro años del periodo evaluado, de 2018 a 2021. En contraste, Pseudomonas aeruginosa aumentó su resistencia frente a piperacilina-tazobactam y carbapenémicos, lo cual fue estadísticamente significativo. CONCLUSIONES: Los cambios en la resistencia antimicrobiana en estos años no han sido estadísticamente significativos, excepto para P. aeruginosa, bacteria que mostró un incremento en las tasas de resistencia a piperacilina-tazobactam y carbapenémicos.


Sujet(s)
Hôpitaux , Pandémies , Colombie/épidémiologie , Pipéracilline , Tazobactam
7.
Biomédica (Bogotá) ; 43(4)dic. 2023.
Article de Espagnol | LILACS-Express | LILACS | ID: biblio-1533958

RÉSUMÉ

Introducción. El comportamiento de la resistencia antimicrobiana es fundamental en el mejoramiento y ajuste de los programas de optimización de uso de antimicrobianos, la implementación de las guías terapéuticas y las precauciones que limitan la transmisión cruzada de bacterias resistentes entre pacientes. Desde el inicio del 2020, la pandemia del SARS-CoV-2 desafió profundamente al sistema de salud y, según algunos reportes, aumentó las tasas de resistencia antimicrobiana. Objetivo. Describir el comportamiento de la resistencia antimicrobiana en los microrganismos más frecuentes en veinte hospitales colombianos durante el periodo 2018-2021. Materiales y métodos. Se trata de un estudio descriptivo basado en la información microbiológica reportada por veinte instituciones de salud de nivel III y IV, entre enero de 2018 y diciembre de 2021, en doce ciudades de Colombia, las cuales hacen parte del "Grupo para el estudio de la resistencia nosocomial en Colombia", liderado por la Universidad El Bosque. La identificación de género y especie de los microorganismos más frecuentes, junto con su perfil de resistencia frente a antibióticos marcadores, se determinaron mediante el análisis de los datos vía WHONET. Resultados. En general, los 10 microorganismos más frecuentes analizados a lo largo de los 4 años no presentaron cambios estadísticamente significativos en sus perfiles de resistencia durante los cuatro años del periodo evaluado, de 2018 a 2021. En contraste, Pseudomonas aeruginosa aumentó su resistencia frente a piperacilinatazobactam y carbapenémicos, lo cual fue estadísticamente significativo. Conclusiones. Los cambios en la resistencia antimicrobiana en estos años no han sido estadísticamente significativos, excepto para P. aeruginosa, bacteria que mostró un incremento en las tasas de resistencia a piperacilina-tazobactam y carbapenémicos.


Introduction. Antimicrobial resistance surveillance is a fundamental tool for the development, improvement, and adjustment of antimicrobial stewardship programs, therapeutic guidelines, and universal precautions to limit the cross-transmission of resistant bacteria between patients. Since the beginning of 2020, the SARS-CoV-2 pandemic profoundly challenged the health system and, according to some reports, increased the rates of antimicrobial resistance. Objective. To describe the behavior of antimicrobial resistance of the most frequent bacterial pathogens in twenty Colombian hospitals from January 2018 to December 2021. Materials and methods. We conducted a descriptive study based on the microbiological information recorded from January 2018 to December 2021 in twenty levels III and IV health institutions in twelve Colombian cities. We identified the species of the ten most frequent bacteria along with their resistance profile to the antibiotic markers after analyzing the data through WHONET. Results. We found no statistically significant changes in most pathogens' resistance profiles from January 2018 to December 2021. Only Pseudomonas aeruginosa had a statistically significant increase in its resistance profile, particularly to piperacillin/ tazobactam and carbapenems. Conclusions. The changes in antimicrobial resistance in these four years were not statistically significant except for P. aeruginosa to piperacillin/tazobactam and carbapenems.

8.
J Antimicrob Chemother ; 78(10): 2591-2596, 2023 10 03.
Article de Anglais | MEDLINE | ID: mdl-37671831

RÉSUMÉ

OBJECTIVES: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials. METHODS: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts. RESULTS: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use. CONCLUSIONS: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.


Sujet(s)
Co-infection , Infections à VIH , Hépatite C chronique , Humains , Antiviraux/pharmacologie , Co-infection/traitement médicamenteux , Co-infection/complications , Hépatite C chronique/complications , Hépatite C chronique/traitement médicamenteux , Infections à VIH/complications , Infections à VIH/traitement médicamenteux , Essais cliniques comme sujet , Études multicentriques comme sujet
9.
Cureus ; 15(8): e44070, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37638261

RÉSUMÉ

Eyebrow micropigmentation, also known as eyebrow microblading or embroidery, is a new technique in the field of semi-permanent cosmetics that are used for therapeutic and aesthetic purposes to recreate eyebrow structure and definition. It uses synthetic pigment that is deposited through fine needles into the papillary dermis and remains till the body metabolizes the pigment and clinically fades away by 12-18 months. Similar to other tattooing procedures, microblading involves risks including local inflammation, infection, allergic contact dermatitis, and granulomatous reactions that can occur from months to years after the procedure. We describe herein a case of a 49-year-old female who has persistent erythematous and indurated plaques on both eyebrows after a microblading procedure performed over a year and a half prior to her initial visit.

10.
Life (Basel) ; 13(8)2023 Aug 10.
Article de Anglais | MEDLINE | ID: mdl-37629571

RÉSUMÉ

Antiepileptic drugs affect embryonic development when administered during pregnancy, generating severe alterations, such as as cleft lip, spina bifida, heart abnormalities, or neuronal alterations. The compound DL-4-hydroxy-4-phenylhexanamide (DL-HEPB), a phenyl alcohol amide structurally different from known anticonvulsants, has shown good anticonvulsant effects in previous studies. However, its effects on intrauterine development are unknown. So, the purpose of this study was to determine the potential of DL-HEPB to produce alterations in conceptus. Pregnant Wistar rats were orally exposed to 0, 50, 100, and 200 mg/kg of DL-HEPB during organogenesis, and their food consumption and weight gain were measured. On gestation day 21, pregnant females were euthanized to analyze the fetuses for external, visceral, and skeletal malformations. A significant decrease in food consumption and body weight was observed in mothers, without any other manifestation of toxicity. In fetuses, no external malformations, visceral, or skeletal abnormalities, were observed under the dose of 100 mg/kg, while the dose of 200 mg/kg caused malformations in low frequency in brain and kidneys. In view of the results obtained, DL-HEPB could be a good starting point for the design of new highly effective anticonvulsant agents, with much lower developmental toxicity than that shown by commercial anticonvulsants.

11.
Antibiotics (Basel) ; 12(8)2023 Aug 21.
Article de Anglais | MEDLINE | ID: mdl-37627762

RÉSUMÉ

Antimicrobial resistance is one of the major global health threats. Antimicrobial stewardship (AMS) has been set as a priority within international action plans to combat this issue. The region of Latin America and the Caribbean are recognized for their high antimicrobial resistance rates; nevertheless, a low number of studies describing implemented interventions for this topic have been published. This review aims to provide an overview of the status of AMS in our region, focusing on the main progress achieved and describing the different published efforts made by countries towards the implementation of antimicrobial stewardship programs (ASP). Common areas of intervention included were (a) education approaches, (b) antimicrobial guideline implementation and monitoring, (c) diagnostic stewardship, (d) technological tools: electronic clinical decision support systems in AMS, (e) pharmacy-driven protocols and collaborative practice agreements, and (f) economic impact. The search demonstrated the varied interventions implemented in diverse healthcare settings; the results accentuate their influence on antimicrobial consumption, antimicrobial resistance, clinical outcomes, and direct economic impact. The integration of multiple strategies within each hospital was highlighted as an essential key to ASP success. Even though the literature found demonstrated clear progress, there is still a special need for strengthening leadership from the top down, defining goals based on needs, and gaining support through policy and financing in LAC.

12.
BMC Infect Dis ; 23(1): 463, 2023 Jul 11.
Article de Anglais | MEDLINE | ID: mdl-37434158

RÉSUMÉ

BACKGROUND: Studies have shown that more than 50% of the antibiotics used in hospitals are unnecessary or inappropriate and, that antimicrobial resistance may cost up to 20 billion USD in excess medical costs each year. On the other hand, Antimicrobial Stewardship Programs (ASP) significantly reduce inappropriate antimicrobial use, emergence of antimicrobial resistance, healthcare associated infections, and costs in hospital settings. OBJECTIVE: To evaluate the development of ASP and antibiotic savings in 7 Latin American hospitals using standardized quantitative indicators in all the participating health care institutions. METHODS: An interventional study was conducted, where pre- and post- evaluations were performed using a standardized score tool adapted from the Joint Commission International accreditation standards and, the Colombian Institute of Technical Standards and Certification. We evaluated ASP from 7 Latin American hospitals between 2019 and 2020. A pre-intervention evaluation was done in each hospital to quantify the degree of development of the ASP (ASP Development score). Based on these results, tailored on-site training was implemented in each hospital, followed by a post-intervention evaluation to quantify improvement of ASP-development indicators. In addition, monetary savings in antimicrobials derived from the ASP intervention were estimated. RESULTS: In the pre-intervention evaluation, the average ASP development score for the 7 institutions was 65.8% (40-94.3%). The items with the lowest development score were those related to monitoring and communicating the ASP progress and success. For the post-intervention evaluation, 2 institutions couldn't participate due to the pressure imposed by the COVID-19 pandemic. For the remaining 5/7 hospitals, the average ASP development score was 82.3% with an increase of 12.0% when compared to the pre-intervention measurement of the same institutions (average pre-intervention score 70.3% (48.2%-94.3%) The items with a significant increase were key performance indicators, AMS education and training of the prescribers. Three of the seven (3/7) hospitals reported antibiotic monetary savings associated to the ASP intervention. CONCLUSIONS: The use of the tool described shown to be useful to evaluate specific areas of ASP-development that were lacking and tailor interventions for the participating hospitals, consequently, it helped improve ASP-development in the institutions that underwent pre- intervention and post-intervention analysis. In addition, the strategies showed monetary savings on antimicrobial costs when measured.


Sujet(s)
Gestion responsable des antimicrobiens , COVID-19 , Humains , Amérique latine , Pandémies , Antibactériens/usage thérapeutique
14.
Infect Dis Ther ; 12(6): 1445-1463, 2023 Jun.
Article de Anglais | MEDLINE | ID: mdl-37261612

RÉSUMÉ

Despite technological advancements in infectious disease rapid diagnostic tests (RDTs) and use to direct therapy at the per-patient level, RDT utilisation in antimicrobial stewardship programmes (ASPs) is variable across low-to-middle income and high-income countries. Key insights from a panel of seven infectious disease experts from Colombia, Japan, Nigeria, Thailand, the UK, and the USA, combined with evidence from a literature review, were used to assess the value of RDTs in ASPs. From this, a value framework is proposed which aims to define the benefits of RDT use in ASPs, separate from per-patient benefits. Expert insights highlight that, to realise the value of RDTs within ASPs, effective implementation is key; actionable advice for choosing an RDT is proposed. Experts advocate the inclusion of RDTs in the World Health Organization Model List of essential in vitro diagnostics and in iterative development of national action plans.

15.
Investig. psicol. (La Paz, En línea) ; (29): 11-27, jun. 2023.
Article de Espagnol | LILACS | ID: biblio-1437559

RÉSUMÉ

Debido al aislamiento social que se vivió gracias a la pandemia por Covid-19, las horas de convivencia familiar aumentaron en cada hogar, convirtiéndose en un potencial peligro cuando el entorno familiar más cercano está lleno de violencia; esto puede traer diversos problemas a la salud física, psicológica y emocional. Por ello, se buscó identificar los principales tipos de violencia familiar que han experimentado los jóvenes universitarios, distinguir entre las conductas externalizantes e internalizantes como consecuencia de estos eventos adversos, así como conocer la relación estadística entre las variables de estudio. La investigación tuvo un enfoque cuantitativo, alcance correlacional y con diseño no experimental transversal; la muestra final estuvo constituida por 374 estudiantes de tres universidades de Lima, Perú. Según los hallazgos, la violencia psicológica es la que se presenta con mayor frecuencia, la ansiedad-depresión y el retraimiento son las dos conductas más comunes y los índices de correlación entre las variables son positivos y significativos. Las mujeres presentan más puntaje en las conductas internalizantes, mientras que los varones en las externalizantes; así mismo, se encontró que los más jóvenes presentan más conductas externalizantes. Finalmente, se evidenció la existencia de violencia familiar en los hogares de los jóvenes universitarios, lo cual se ha traducido en diversos tipos de conducta que podrían afectar su salud y también su rendimiento académico.


Due to the social isolation that was experienced thanks to the Covid-19 pandemic, the hours of family life increased in each home, becoming a potential danger when the closest family environment is full of violence; this can bring various problems to physical, psychological and emotional health. Therefore, we sought to identify the main types of family violence that university students have experienced, distinguish between externalizing and internalizing behaviors as a consequence of these adverse events, as well as knowing the statistical relationship between the study variables. The research was a quantitative, correlational and a non-experimental cross-sectional design; the sample consisted of 374 students from three universities in Lima, Peru. According to the findings, psychological violence is the one that occurs most frequently, anxiety-depression and withdrawal are the two most common behaviors and the correlation rates between the variables are positive and significant. Women present higher scores in internalizing behaviors, while men in externalizing ones; Likewise, it was found that the youngest present more externalizing behaviors. The existence of family violence in the homes of university students was evidenced, which has resulted in various types of behavior that could affect their health and also their academic performance.


Sujet(s)
Humains , Mâle , Femelle , Adulte
16.
Medisur ; 21(3)jun. 2023.
Article de Espagnol | LILACS-Express | LILACS | ID: biblio-1448676

RÉSUMÉ

Fundamento: mejorar la higiene de las manos de manera eficaz y sostenida se consigue mediante la aplicación de múltiples medidas para abordar diferentes obstáculos, así como barreras conductuales, es por ello que se hace necesario crear medios que permitan su aprendizaje. Objetivo: diseñar medios de enseñanza que contribuyan al aprendizaje de la higiene de manos tanto en estudiantes de Lic. en Enfermería como en la comunidad. Métodos: se desarrolló una investigación cualicuantitativa, durante el período de estudio de junio 2018 a julio 2021. Los escenarios fueron el Círculo Infantil Marineritos del Sur, Escuela Primaria Guerrillero Heroico y la Universidad de Ciencias Médicas en el municipio de Cienfuegos. Se realizaron grupos de discusión en los tres escenarios, de lo cual emergieron las categorías capacitación y medios de enseñanza, que fueron creados y validados por la metodología de Barraza. Resultados: se diseñó una página web, una aplicación para móvil, juegos didácticos para los niños y trípticos. Todos fueron validados satisfactoriamente. Conclusiones: el diseño de medios de enseñanza, sustentados científicamente, se corresponde con las necesidades de los estudiantes la carrera de Licenciatura en Enfermería y de la comunidad para el logro de los conocimientos teóricos y prácticos en la adherencia a la técnica correcta de higiene de manos.


Summary: Introduction: The improvement of effective and sustained hand hygiene is achieved through the application of multiple measures to address different obstacles, as well as behavioral barriers, which is why it is necessary to create means that allow the learning of it, in such a way. In this sense, the objective is to design teaching means that contribute to the learning of hand hygiene both in Nursing students and in the community, Method; a qualitative-quantitative investigation was developed, Results the qualitative phase was evidenced when a discussion group was carried out from which the category training and teaching aids emerged, which allowed the design of a web page, a mobile application, didactic games for children and triptychs, and the quantitative phase when said teaching aids were validated by the Barraza methodology.

17.
J Alzheimers Dis ; 92(4): 1303-1321, 2023.
Article de Anglais | MEDLINE | ID: mdl-37038810

RÉSUMÉ

BACKGROUND: Neuropsychological assessments are essential to define the cognitive profile and contribute to the diagnosis of Alzheimer's disease (AD). The progress in knowledge about the pathophysiological process of the disease has allowed conceptualizing AD through biomarkers as a biological continuum that encompasses different clinical stages. OBJECTIVE: To explore the association between cerebrospinal fluid (CSF) biomarkers of AD and cognition using the NEURONORMA battery, in a sample of cognitively unimpaired (CU), mild cognitive impaired (MCI), and mild dementia of the Alzheimer type (DAT) subjects, and to characterize the cognitive profiles in MCI subjects classified by A/T/N system. METHODS: 42 CU, 35 MCI, and 35 mild DAT were assessed using the NEURONORMA battery. Core AD biomarkers [amyloid-ß42 (Aß42) peptide, total tau (t-tau), and phosphorylated tau 181 (p-tau181)] proteins were measured in CSF. Correlation coefficients, multivariate regression, and effect sizes were calculated. We explored the age- and education-adjusted cognitive profiles by A/T/N variants within the MCI group. RESULTS: Cognitive outcomes were directly associated with CSF Aß42 and inversely with CSF tau measures. We found differences in both biomarkers and cognitive outcomes comparing all pairs except for CSF measures between cognitively impaired groups. The highest effect size was in memory tasks and biomarkers ratios. Lower performances were in memory and executive domains in MCI subjects with AD pathology (A+T+N±) compared to those with normal levels of AD biomarkers (A- T- N). CONCLUSION: This study provides further evidence of the validity of Spanish NEURONORMA cognitive battery to characterize cognitive impairment in the AD pathological continuum.


Sujet(s)
Maladie d'Alzheimer , Dysfonctionnement cognitif , Humains , Maladie d'Alzheimer/anatomopathologie , Peptides bêta-amyloïdes/liquide cérébrospinal , Marqueurs biologiques/liquide cérébrospinal , Cognition , Dysfonctionnement cognitif/psychologie , Évolution de la maladie , Fragments peptidiques/liquide cérébrospinal , Protéines tau/liquide cérébrospinal
18.
mSphere ; 8(2): e0065122, 2023 04 20.
Article de Anglais | MEDLINE | ID: mdl-36877058

RÉSUMÉ

Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-ß-lactam ß-lactamase inhibitor capable of inactivating class A, C, and some D ß-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (blaOXA-50-like), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms.


Sujet(s)
Ceftazidime , Infections à Pseudomonas , Humains , Ceftazidime/pharmacologie , Pseudomonas aeruginosa , Amérique latine , Antibactériens/pharmacologie , Hôpitaux
19.
Antibiotics (Basel) ; 12(3)2023 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-36978355

RÉSUMÉ

We report the presence of the mcr-1 gene among 880 Escherichia coli clinical isolates collected in 13 hospitals from 12 Colombian cities between 2016 and 2019. Seven (0.8%) isolates were colistin resistant (MIC ≥ 4 µg/mL). These colistin-resistant isolates were screened for the presence of the mcr-1 gene; five carried the gene. These five isolates were subjected to whole genome sequencing (WGS) to identify additional resistomes and their ST. In addition, antimicrobial susceptibility testing revealed that all E. coli isolates carrying mcr-1 were susceptible to third generation-cephalosporin and carbapenems, except one, which carried an extended-spectrum ß-lactamase (CTX-M-55), along with the fosfomycin resistance encoding gene, fosA. WGS indicated that these isolates belonged to four distinct sequence types (ST58, ST46, ST393, and a newly described ST14315) and to phylogroups B1, A, and D. In this geographic region, the spread of mcr-1 in E. coli is low and has not been inserted into high-risk clones such as ST131, which has been present in the country longer.

20.
Genes (Basel) ; 14(3)2023 02 21.
Article de Anglais | MEDLINE | ID: mdl-36980810

RÉSUMÉ

STAT4 plays an important role in disease activity in SLE patients. STAT4 particles have the capacity to activate the transcription of genes associated with the production of TH1 and Th17 lymphocytes, with a greater predominance on the production of IFN-γ and IL-17A. The presence of variants in STAT4 genes has a major impact on the generation of autoimmunity. However, there are few studies evaluating the impact of these variants on the production of proinflammatory cytokines such as IFN-γ and IL-17A. Methods-A case-control study was carried out with 206 Mexican mestizo patients residing in Western Mexico with a diagnosis of SLE and a group of 80 patients without autoimmune diseases was captured to determine the cut-off point for high IFN-γ levels. In this study, SLE patients with high IFN-γ levels were considered as cases (cut-off > 15.6 pg/mL), and SLE patients with normal IFN-γ levels were considered as controls (cut-off ≤ 15.6 pg/mL). Disease activity was identified from the systemic lupus erythematosus disease activity index (SLEDAI). For the determination of levels of cytokines IFN-γ, IL-12, and IL17A, commercial ELISA kits were used. Genotyping of STAT4 rs7574865 (G > T) was performed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. Results-The patients with SLE had a median age of 45 years with a range of disease duration from 4 years to 18 years; 45.6% were identified as having disease activity. In this sample, we identified a high IFN-γ prevalence of 35.4%. The levels of IFN-γ were higher in the patients with genotype TT than GG. We found that TT genotype conferred a higher risk of high IFN-γ when compared to the GG and GT genotypes. Conclusions-In this study, we identified that the polymorphic genotype TT of the STAT4 gene rs7574865 polymorphism is associated with increased levels of IFN-γ. However, its strength of association was weak, so complementary studies are needed to evaluate its impact on SLE patients.


Sujet(s)
Maladies auto-immunes , Interféron gamma , Lupus érythémateux disséminé , Facteur de transcription STAT-4 , Enfant d'âge préscolaire , Humains , Allèles , Maladies auto-immunes/génétique , Maladies auto-immunes/métabolisme , Études cas-témoins , Cytokines/génétique , Prédisposition génétique à une maladie , Interféron gamma/génétique , Interleukine-17/génétique , Lupus érythémateux disséminé/génétique , Lupus érythémateux disséminé/métabolisme , Polymorphisme de nucléotide simple , Facteur de transcription STAT-4/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...